XNK Therapeutics granted SEK1m by Sweden’s Vinnova
XNK Therapeutics AB (“XNK”) today announced that Vinnova, a Swedish government-sponsored innovation agency, has granted XNK SEK1 million to upscale production of CellProtect. “We are extremely…
XNK Therapeutics’ patent for expansion of NK cells granted in Korea
XNK Therapeutics AB (“XNK”) today announced that Korea has granted the company a patent for its process of expanding NK cells. The patent covers XNK’s production methods for expansion and…
XNK Therapeutics becomes a partner in Swelife’s health economics project
XNK Therapeutics AB (“XNK”) today announced it has become a partner in Swelife’s health economics project on Advanced Therapy Medicinal Products (ATMP). The partnership allows the company to…
Agneta Edberg appointed to board of XNK Therapeutics
XNK Therapeutics AB (“XNK”) today announced it strengthened its organization by appointing Agneta Edberg to the board of directors. Agneta Edberg has over 25 years’ experience from leading…
XNK Therapeutics granted SEK1m by Sweden’s Vinnova to partner in AdBIOPRO
XNK Therapeutics AB (“XNK”) today announced that the Swedish government-sponsored innovation agency Vinnova has granted XNK SEK1 million to partner in The Competence Centre for Advanced…